It is of interest to note that in melanoma patients treated with the BRAF inhibitor vemurafenib, pre-existing BRAFV600E mutant melanocytic nevi either remained unchanged, regressed, or exhibited increased pigmentation. The gene discussed is BRAF; the disease is melanoma.